Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 5
2022 4
2023 8
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Archival single-cell genomics reveals persistent subclones during DCIS progression.
Wang K, Kumar T, Wang J, Minussi DC, Sei E, Li J, Tran TM, Thennavan A, Hu M, Casasent AK, Xiao Z, Bai S, Yang L, King LM, Shah V, Kristel P, van der Borden CL, Marks JR, Zhao Y, Zurita AJ, Aparicio A, Chapin B, Ye J, Zhang J, Gibbons DL; Grand Challenge PRECISION Consortium; Sawyer E, Thompson AM, Futreal A, Hwang ES, Wesseling J, Lips EH, Navin NE. Wang K, et al. Cell. 2023 Aug 31;186(18):3968-3982.e15. doi: 10.1016/j.cell.2023.07.024. Epub 2023 Aug 15. Cell. 2023. PMID: 37586362 Free article.
Mechanisms that clear mutations drive field cancerization in mammary tissue.
Ciwinska M, Messal HA, Hristova HR, Lutz C, Bornes L, Chalkiadakis T, Harkes R, Langedijk NSM, Hutten SJ, Menezes RX, Jonkers J, Prekovic S; Grand Challenge PRECISION consortium; Simons BD, Scheele CLGJ, van Rheenen J. Ciwinska M, et al. Nature. 2024 Sep;633(8028):198-206. doi: 10.1038/s41586-024-07882-3. Epub 2024 Sep 4. Nature. 2024. PMID: 39232148 Free PMC article.
Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.
Schmitz RSJM, van den Belt-Dusebout AW, Clements K, Ren Y, Cresta C, Timbres J, Liu YH, Byng D, Lynch T, Menegaz BA, Collyar D, Hyslop T, Thomas S, Love JK, Schaapveld M, Bhattacharjee P, Ryser MD, Sawyer E, Hwang ES, Thompson A, Wesseling J, Lips EH, Schmidt MK; Grand Challenge PRECISION consortium. Schmitz RSJM, et al. BMJ. 2023 Oct 30;383:e076022. doi: 10.1136/bmj-2023-076022. BMJ. 2023. PMID: 37903527 Free PMC article.
Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.
Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, Shah V, Hoogstraat M, Sei E, Mallo D, Roman-Escorza M, Ahmed AA, Xu M, van den Belt-Dusebout AW, Brugman W, Casasent AK, Clements K, Davies HR, Fu L, Grigoriadis A, Hardman TM, King LM, Krete M, Kristel P, de Maaker M, Maley CC, Marks JR, Menegaz BA, Mulder L, Nieboer F, Nowinski S, Pinder S, Quist J, Salinas-Souza C, Schaapveld M, Schmidt MK, Shaaban AM, Shami R, Sridharan M, Zhang J, Stobart H, Collyar D, Nik-Zainal S, Wessels LFA, Hwang ES, Navin NE, Futreal PA; Grand Challenge PRECISION consortium; Thompson AM, Wesseling J, Sawyer EJ. Lips EH, et al. Nat Genet. 2022 Jun;54(6):850-860. doi: 10.1038/s41588-022-01082-3. Epub 2022 Jun 9. Nat Genet. 2022. PMID: 35681052 Free PMC article.
A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression.
Hutten SJ, de Bruijn R, Lutz C, Badoux M, Eijkman T, Chao X, Ciwinska M, Sheinman M, Messal H, Herencia-Ropero A, Kristel P, Mulder L, van der Waal R, Sanders J, Almekinders MM, Llop-Guevara A, Davies HR, van Haren MJ, Martin NI, Behbod F, Nik-Zainal S, Serra V, van Rheenen J, Lips EH, Wessels LFA; Grand Challenge PRECISION Consortium; Wesseling J, Scheele CLGJ, Jonkers J. Hutten SJ, et al. Cancer Cell. 2023 May 8;41(5):986-1002.e9. doi: 10.1016/j.ccell.2023.04.002. Epub 2023 Apr 27. Cancer Cell. 2023. PMID: 37116492 Free PMC article.
Learning to distinguish progressive and non-progressive ductal carcinoma in situ.
Casasent AK, Almekinders MM, Mulder C, Bhattacharjee P, Collyar D, Thompson AM, Jonkers J, Lips EH, van Rheenen J, Hwang ES, Nik-Zainal S, Navin NE, Wesseling J; Grand Challenge PRECISION Consortium. Casasent AK, et al. Nat Rev Cancer. 2022 Dec;22(12):663-678. doi: 10.1038/s41568-022-00512-y. Epub 2022 Oct 19. Nat Rev Cancer. 2022. PMID: 36261705 Review.
Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.
Schmitz RSJM, Engelhardt EG, Gerritsma MA, Sondermeijer CMT, Verschuur E, Houtzager J, Griffioen R, Retèl V, Bijker N, Mann RM, van Duijnhoven F, Wesseling J, Bleiker EMA; Grand Challenge PRECISION Consortium. Schmitz RSJM, et al. Eur J Cancer. 2023 Oct;192:113276. doi: 10.1016/j.ejca.2023.113276. Epub 2023 Aug 4. Eur J Cancer. 2023. PMID: 37657228 Free PMC article.
Microcalcification crystallography as a potential marker of DCIS recurrence.
Gosling SB, Arnold EL, Davies SK, Cross H, Bouybayoune I, Calabrese D, Nallala J, Pinder SE, Fu L, Lips EH, King L, Marks J, Hall A, Grimm LJ, Lynch T, Pinto D, Stobart H, Hwang ES, Wesseling J, Geraki K, Stone N, Lyburn ID, Greenwood C, Rogers KD; Grand Challenge PRECISION Consortium. Gosling SB, et al. Sci Rep. 2023 Jun 8;13(1):9331. doi: 10.1038/s41598-023-33547-8. Sci Rep. 2023. PMID: 37291276 Free PMC article.
Artificial intelligence-based morphometric signature to identify ductal carcinoma in situ with low risk of progression to invasive breast cancer.
Sobral-Leite M, Castillo S, Vonk S, Melillo X, Lam N, de Bruijn B, Hagos Y, Sanders J, Almekinders M, Visser L, Groen E, Kristel P, Ercan C, Azarang L, Yuan Y; Grand Challenge PRECISION Consortium; Menezes R, Lips E, Wesseling J. Sobral-Leite M, et al. Res Sq [Preprint]. 2023 Dec 13:rs.3.rs-3639521. doi: 10.21203/rs.3.rs-3639521/v1. Res Sq. 2023. PMID: 38168198 Free PMC article. Preprint.
21 results